The Groundbreaking Achievement at Kobe University

Researchers at Kobe University have achieved a world-first milestone in synthetic biology by engineering common gut bacteria, Escherichia coli (E. coli), to produce orsellinic acid (OSA)—the core precursor for a class of promising pharmaceuticals derived from Rhododendron plants. This innovation addresses longstanding supply chain issues for these valuable compounds, paving the way for scalable drug development.

Orsellinic acid-derived meroterpenoids, naturally found in Rhododendron species like Rhododendron dauricum, exhibit potent anticancer, anti-HIV, antidiabetic, and anti-inflammatory properties. Previously, extracting them from plants was inefficient, environmentally taxing, and yield-variable. Now, bioengineered E. coli offers a stable, cost-effective alternative, marking a leap forward for Japan's higher education-led biotech innovations.

Understanding Orsellinic Acid-Derived Meroterpenoids

Meroterpenoids are hybrid natural products combining polyketide and terpenoid moieties. Orsellinic acid (OSA), a phenolic polyketide, serves as the backbone for this subclass, produced via type III polyketide synthase (PKS) enzymes in plants such as Rhododendron. Key examples include grifolic acid (GFA) with strong anticancer and analgesic effects, daurichromenic acid (anti-HIV), capitachromenic acid, and anthopogochromenes.

These compounds' bioactivities stem from their ability to interact with cellular pathways: GFA inhibits tumor cell proliferation, while others target viral reverse transcriptase or inflammatory cytokines. Despite potential, natural sourcing limited research—yields as low as 0.1% dry weight in plants, fluctuating with season, habitat, and species protection status.

In Japan, where biodiversity conservation is paramount, this bacterial platform aligns with sustainable biotech goals, reflecting higher education's role in green innovation.

Challenges in Traditional Extraction from Rhododendron

Rhododendron species thrive in Japan's mountainous regions, but harvesting poses hurdles: destructive collection harms ecosystems, chemical variability requires laborious purification, and low concentrations demand tons of biomass per gram of compound. For instance, protected species like Rhododendron dauricum face regulatory bans, exacerbating shortages.

• Environmental impact: Overharvesting threatens biodiversity hotspots.
• Economic barriers: Purification costs exceed $10,000 per gram for rare meroterpenoids.
• Supply inconsistency: Seasonal yields vary 5-10 fold.

Prior microbial attempts in fungi like Aspergillus oryzae yielded mere 5 mg/L OSA, insufficient for pharma-scale evaluation. Kobe University's approach flips this script using E. coli, a GRAS (Generally Recognized As Safe) organism favored in industry.

Step-by-Step Engineering of the Biosynthetic Pathway

The team, led by Prof. Tomohisa Hasunuma, meticulously reconstructed the eukaryotic pathway in prokaryotic E. coli. Here's the process:

1. PKS Module Introduction: Cloned ORS (type III PKS from R. dauricum) and OAC (cyclase from Cannabis sativa) for de novo OSA from acetyl-CoA and malonyl-CoA.
2. CRISPRi Optimization: Knocked down fadR gene (fatty acid regulator) to redirect malonyl-CoA, boosting OSA 8-fold to 15 mg/L.
3. Precursor Supply Enhancement: Overexpressed acetyl-CoA carboxylase (ACC from Corynebacterium glutamicum), pantothenate kinase (CoaA from Pseudomonas putida), and ATP-citrate lyase (ACL from Aspergillus nidulans).
4. Prenyltransferase Addition: Added RdPT1 from R. dauricum for GFA production.
5. Culture Tuning: 20°C, TB media + 40 g/L glucose, 0.2 mM IPTG induction—yielding peak titers.

Metabolomics via LC-MS/MS pinpointed bottlenecks like malonyl-CoA depletion, guiding iterative improvements.Read the full paper

Impressive Results and Production Yields

The engineered strain achieved 202 mg/L OSA—a 40-fold leap over prior records and first in E. coli. Productivity hit 4.0 mg/L/h, with 6.1 mg/g-glucose yield. GFA reached 2.5 μg/g dry cell weight (DCW), proving feasibility despite low titer needing refinement.

• OSA: 202 mg/L (supernatant), 145 mg/L intracellular.
• Orcinol byproduct: 140 mg/L (future blockable).
• Scale potential: E. coli's fast growth (doubling 20 min) suits fermenters.

These metrics position the platform for pilot-scale pharma trials, showcasing Kobe's metabolic engineering prowess.

Spotlight on the Research Team

Prof. Tomohisa Hasunuma, Director of Kobe University's Engineering Biology Research Center, brings expertise in microbial metabolic engineering from microalgae biofuels to complex compound bioproduction. His lab has pioneered AI-genome editing for carbon-neutral biomanufacturing.

First author Itsuki Tomita, a doctoral student, drove the project: "Recreating a complex eukaryotic pathway in E. coli was thought difficult, but we succeeded." Collaborators include Takahiro Bamba (RIKEN), Lucília Domingues (University of Minho), and others from Kobe's Graduate School of Science, Technology and Innovation.

This interdisciplinary effort exemplifies Japan's university-industry synergies, funded by JSPS J-PEAKS and JST.Explore research jobs at leading Japanese universities

Implications for Global Pharmaceutical Development

This platform unlocks evaluation of 50+ OSA-derivatives, accelerating leads for oncology, antivirals, and inflammation therapies. In Japan, where biotech R&D funding hit ¥1.2 trillion in 2026, such advances bolster the sector's 15% CAGR.

• Cost reduction: Fermentation vs. extraction saves 90%.
• Sustainability: No plant depletion.
• Customization: Engineer variants for potency.

Pharma giants like Takeda could license for HIV/anticancer pipelines. For aspiring researchers, opportunities abound in higher ed research assistant roles.

Kobe University's Role in Japan's Biotech Higher Education Landscape

Kobe University, rooted in 1902 as Kobe Higher Commercial School, now excels in biotech via centers like Engineering Biology Research Center. Amid Japan's Moonshot R&D (¥100B+ annually), Kobe secures JSPS grants, fostering talents for Japanese university jobs.

2026 funding trends emphasize bioeconomy, with universities producing 30% of patents. This Rhododendron project highlights metabolic engineering's rise, training PhDs like Tomita for industry.

Future Outlook: Optimizations and Expansions

Next steps: Block orcinol shunt, boost FPP for prenylation (MEP pathway), DoE for 1 g/L OSA. Extend to anti-HIV daurichromenic acid. Hasunuma envisions: "A foundational tech for complex compounds."

Timeline: Pilot fermenters 2027, clinical candidates 2030. For students, craft a winning academic CV to join such labs.

Photo by Da-shika on Unsplash

Career Opportunities in Biotech Research

This breakthrough underscores demand for experts in synthetic biology. Japan’s universities offer postdoc positions, faculty roles, and professor jobs. Explore Rate My Professor for insights, or higher ed career advice to advance.